EIF5A2 Antikörper (C-Term)

Produktnummer ABIN966053

Produktdetails anti-EIF5A2 Antikörper

Target: EIF5A2 (Eukaryotic Translation Initiation Factor 5A2 (EIF5A2))

Bindungsspezifität: C-Term

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser EIF5A2 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC)

Immunogen: Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to C-terminal residues of human EIF5A2

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Referenzen für anti-EIF5A2 Antikörper (ABIN966053)

Luo, Hua, Rao, Liao, Kung, Zeng, Guan, Chen, Xie: "Overexpression of EIF-5A2 predicts tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder." in: Cancer science, Vol. 100, Issue 5, pp. 896-902, (2009) (PubMed).

Chen, Luo, Hua, Zhou, Lin, Kung, Zeng, Guan, Xie: "Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy." in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 18, Issue 2, pp. 400-8, (2009) (PubMed).

Yang, Xie, Liu, Luo, Li, Hua, Wu, Kung, Zeng, Guan: "Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma." in: Gynecologic oncology, Vol. 112, Issue 2, pp. 314-8, (2009) (PubMed).

Xie, Ma, Pan, Wu, Liu, Wu, Kung, Guan: "Overexpression of EIF-5A2 is associated with metastasis of human colorectal carcinoma." in: Human pathology, Vol. 39, Issue 1, pp. 80-6, (2007) (PubMed).

Ojima, Inoue, Miki, Mori, Kusunoki: "Effectiveness of gene expression profiling for response prediction of rectal cancer to preoperative radiotherapy." in: Journal of gastroenterology, Vol. 42, Issue 9, pp. 730-6, (2007) (PubMed).

Andersen, Lam, Leung, Ong, Lyon, Lamond, Mann: "Nucleolar proteome dynamics." in: Nature, Vol. 433, Issue 7021, pp. 77-83, (2005) (PubMed).

Guan, Fung, Ma, Lau, Tai, Xie, Zhang, Hu, Wu, Fang, Sham: "Oncogenic role of eIF-5A2 in the development of ovarian cancer." in: Cancer research, Vol. 64, Issue 12, pp. 4197-200, (2004) (PubMed).

Details zu EIF5A2

Target: EIF5A2 (Eukaryotic Translation Initiation Factor 5A2 (EIF5A2))

Andere Bezeichnung: EIF5A2 (EIF5A2 Produkte)

Synonyme: EIF5A2 antikoerper, EIF5A antikoerper, zgc:55504 antikoerper, zgc:77429 antikoerper, wu:fb05b06 antikoerper, wu:fc23f04 antikoerper, wu:fc61c10 antikoerper, EIF-5A2 antikoerper, eIF5AII antikoerper, 9630038B20 antikoerper, eukaryotic translation initiation factor 5A2 antikoerper, eukaryotic translation initiation factor 5A3 antikoerper, EIF5A2 antikoerper, eif5a2 antikoerper, LOC100499632 antikoerper, Eif5a2 antikoerper

Hintergrund: EIF5A2 (Eukaryotic initiation factor 5A ) stimulates ribosomal peptidyltransferase activity, transport of HIV-1-mRNAs and binds exportins 1 and 4. Contains hypusine at lys 50. Human EIF5A1 and EIF5A2 encode two isoforms: eIF5AI and eIF5AII. Increased expression of EIF-5A2 in ovarian carcinoma may represent an acquired malignant phenotypic feature of tumor cells. Overexpression of EIF5A2 is an independent molecular marker for shortened survival time of patients with ovarian carcinoma.